CLINICAL STUDY RESULTS
In 2 large phase 3 trials, SARCLISA was proven to help more people live progression free
Trial 1: SARCLISA + Kd (Kyprolis® [carfilzomib] and dexamethasone)
people treated with SARCLISA + Kd lived progression free
At an average follow-up of 20.7 months, 74% (133 of 179 people) lived progression free with SARCLISA + Kd vs 59% (73 of 123 people) treated with Kd alone.
Trial 2: SARCLISA + Pd (Pomalyst® [pomalidomide] and dexamethasone)
of people treated with SARCLISA + Pd lived progression free
At an average follow-up of 11.6 months, 53% (81 of 154 people) lived progression free with SARCLISA + Pd vs 42% (64 of 153 people) treated with Pd alone.
At this time, there are not enough data available from the trials to assess whether people receiving SARCLISA + Kd or SARCLISA + Pd lived longer.
Trial 1: In a clinical trial of 302 people with previously treated multiple myeloma who had received 1 to 3 prior treatments, 179 people received SARCLISA + Kd and 123 people received Kd alone.
Trial 2: In a clinical trial of 307 people with previously treated multiple myeloma who had received at least 2 prior treatments, including Revlimid® (lenalidomide) and a proteasome inhibitor,* 154 people received SARCLISA + Pd and 153 people received Pd alone.
Both trials compared how long people lived without their disease getting worse and how people responded to treatment.
*Examples of proteasome inhibitors include Kyprolis, Ninlaro® (ixazomib), and Velcade® (bortezomib).
The majority of people responded to treatment with SARCLISA
Trial 1: SARCLISA + Kd
responded to SARCLISA + Kd
83% responded to treatment with Kd alone. The difference between SARCLISA + Kd and Kd alone was not statistically meaningful.
Trial 2: SARCLISA + Pd
responded to SARCLISA + Pd
vs 35% responded to treatment with Pd alone.
